Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers G > Headlines for Genentech Inc. > News item |
Genentech maintained at neutral by Merrill
Merrill Lynch analyst Eric Ende gave Genentech, Inc. a neutral rating on the likelihood that Tykerb is likely to compete with Herceptin. The analyst also expects increased pricing and reimbursement pressures. Shares of the South San Francisco, Calif.-based pharmaceutical company were down $2.00, or 2.43%, at $80.29 on volume of 3,004,690 shares versus the three-month running average of 3,537,690 shares. (NYSE: DNA).
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.